Eli Lilly presents retatrutide, Foundayo and eloraTZP data at EASD 2026

Key highlights
  • TRIUMPH-2: retatrutide (GIP/GLP-1/glucagon triple agonist) produced mean weight loss up to 49.6 lbs (22.5 kg; 20.8%) and A1C reduction up to 1.6% at 80 weeks.
  • ACHIEVE-4: Foundayo (orforglipron) was non-inferior to insulin glargine and showed a 16% lower risk of MACE-4 (HR 0.84; 95.0% CI 0.59–1.20) and 23% lower risk of MACE-3 (HR 0.77; 95.0% CI 0.52–1.13).
  • EloraTZP (eloralintide + tirzepatide): Phase 1 addition of eloralintide 3 mg to tirzepatide 5 mg yielded 17% weight loss over 16 weeks versus 10% with tirzepatide 5 mg alone.
  • SURPASS-CVOT: Mounjaro (tirzepatide) showed non-inferiority vs Trulicity with an 8% lower MACE-3 risk (HR 0.92; 95.3% CI 0.83–1.01) while delivering greater A1C and weight reductions.

Event

Eli Lilly will present new cardiometabolic data at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Sept 28–Oct 2, 2026, and will host an industry symposium on Sept 28 (10:00–16:00 CEST) chaired by Prof. Rachel Batterham.

Retatrutide (TRIUMPH-2)

Phase 3 TRIUMPH-2 results for retatrutide, an investigational once-weekly GIP/GLP-1/glucagon triple receptor agonist, showed adults with obesity or overweight and type 2 diabetes lost up to an average 49.6 lbs (22.5 kg; 20.8%) and lowered A1C by up to an average 1.6% at 80 weeks.

Foundayo (ACHIEVE program)

ACHIEVE-4 showed Foundayo (orforglipron) met non-inferiority versus insulin glargine and signaled potential cardiovascular benefit with a 16% lower risk of MACE-4 (HR 0.84; 95.0% CI 0.59–1.20) and a 23% lower risk of MACE-3 (HR 0.77; 95.0% CI 0.52–1.13). Other ACHIEVE analyses reported faster time-to-goal A1C and weight outcomes versus dapagliflozin and oral semaglutide.

EloraTZP, Mounjaro and Zepbound

EloraTZP, a combination of the selective amylin receptor agonist eloralintide and tirzepatide, will have Phase 2 data presented; prior Phase 1 data showed adding eloralintide 3 mg to tirzepatide 5 mg produced 17% weight loss over 16 weeks versus 10% with tirzepatide 5 mg alone. Mounjaro (SURPASS-CVOT) demonstrated an 8% lower MACE-3 risk versus Trulicity (HR 0.92; 95.3% CI 0.83–1.01) alongside greater A1C and weight reductions, and Zepbound (SURMOUNT-5) produced distinct proteomic changes versus semaglutide in exploratory analyses.

Source: Lilly

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

8 June 2026
Lilly's Foundayo (orforglipron) outperforms oral semaglutide, dapagliflozin and placebo in ACHIEVE trials

Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.

30 September 2026
Lilly’s Foundayo shows cardiovascular safety and durable A1C and weight benefits in ACHIEVE‑4

Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.

30 September 2026
Lilly's EloraTZP (eloralintide + tirzepatide) outperforms tirzepatide 15 mg in Phase 2b obesity and T2D trial

Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.

29 September 2026
Lilly retatrutide shows large weight loss and A1C reductions in TRIUMPH-2

Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.

23 July 2026
Lilly's retatrutide shows large weight and A1C reductions in Phase 3 TRIUMPH‑2 and TRIUMPH‑3

First‑in‑class triple agonist delivered large 80‑week weight losses and meaningful A1C and cardiometabolic improvements in difficult‑to‑treat obesity populations.